


Please type a plus sign (+) in this box



Modified Form 1449/870

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/826,077
Filing Date	April 15, 2004
First Named Inventor	Stanton
Group Art Unit	1045 1635
Examiner Name	Not Yet Assigned
Attorney Docket Number	23239-531 CIP

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
TV	*A1	5,589,332	12/31/96	Shih, et al.	435	6	
	*A2	5,683,867	11/04/97	Biesecker, et al.	435	6	
	*A3	5,705,337	01/06/98	Gold, et al.	435	6	
	*A4	5,723,594	03/03/98	Janjic, et al.	536	23.1	
	*A5	5,834,186	11/10/98	George, et al.	435	6	
	*A6	6,083,696	07/04/00	Biesecker, et al.	435	6	
	*A7	6,232,071 B1	05/15/01	Hicke, et al.,	435	6	

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
TV	*A8	2002/0034506 A1	03/21/02	Pietras, et al.	424	94.63	

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
TV	*B1	WO 98/08974	INTELLIGENE LTD.	03/05/98	
	*B2	WO 98/27104	YALE UNIVERSITY	06/25/98	
	*B3	WO 99/31276	NEXSTAR PHARMACEUTICALS, INC.	06/24/99	
	*B4	WO 00/70329	BRANDEIS UNIVERSITY	11/23/00	
	*B5	WO 01/66721 A2	RIBOZYME PHARMACEUTICALS, INC.	09/13/01	
	*B6	WO 02/22882 A2	ARCHEMIX CORPORATION	03/21/02	
	*B7	WO 03/014375 A2	ARCHEMIX CORPORATION	02/20/03	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
TV	*C1	Breaker, R.R., <i>Curr. Opin. Biotech.</i> , 7:442-448 (1996).
	*C2	Breaker, R.R., <i>Chem. Rev.</i> , 97:371-390 (1997).
	*C3	Breaker, R.R., <i>Curr. Opin. Chem. Biol.</i> , 1:26-31 (1997).
	*C4	Breaker, R.R., <i>Nat. Biotech.</i> , 15:427-431 (1997).
	*C5	Breaker, R.R., <i>Intracellular Ribozyme Applications in Principles and Protocols</i> , pgs. 1-19; Horizon Scientific Press, Wymondham UK, Rossi and Couture, eds., (1999).
	*C6	Breaker, R.R., <i>Curr. Opin. Biotech.</i> , 13:31-39 (2002).
	*C7	Carmi, et al. <i>Chem. & Biol.</i> , 3:1039-1046 (1996).
	*C8	Gold, L., <i>Nat. Biotech.</i> , 20: 671-672 (2002).
	*C9	Hamaguchi, et al., <i>Anal. Biochem.</i> , 294:126-131 (2001).

TV	*C10	Hartig, et al., <i>Nat. Biotech.</i> , 20:717-722 (2002).
	*C11	Jenne, et al., <i>Nat. Biotech.</i> , 19:56-61 (2001).
	*C12	Koizumi, et al., <i>Nucl. Acids Symp. Ser.</i> , 42:275-276 (1999).
	*C13	Koizumi, et al., <i>Nat. Struct. Biol.</i> , 6(11):1062-1071 (1999).
	*C14	Lewis, et al., <i>Bioconjug. Chem.</i> , 12(2):320-324 (2001).
	*C15	Li, et al., <i>Curr. Opin. Struct. Biol.</i> , 9:315-323 (1999).
	*C16	Li, et al., <i>Proc. Natl. Acad. Sci. USA</i> , 96:2746-2751 (1999).
	*C17	Marshall, et al., <i>Nat. Struct. Biol.</i> , 6(11):992-994 (1999).
	*C18	Potyralo, et al., <i>Anal. Chem.</i> , 70:3419-3425 (1998).
	*C19	Raddatz, et al., <i>Nucl. Acids Res.</i> , 30(21):4793-4802 (2002).
	*C20	Robertson, et al., <i>Nucl. Acids Res.</i> , 28(8):1751-1759 (2000).
	*C21	Robertson, et al., <i>Nat. Biotech.</i> , 17:62-66 (1999).
	*C22	Robertson, et al., <i>Nat. Biotech.</i> , 19:650-655 (2001).
	*C23	Sassanfar, et al., <i>Nature</i> , 364:550-553 (1993).
	*C24	Seetharaman, et al., <i>Nat. Biotech.</i> , 19:336-341 (2001).
	*C25	Seiwert, et al., <i>Chem. & Biol.</i> , 7:833-843 (2000).
	*C26	Soukup, et al., <i>Proc. Natl. Acad. Sci. USA</i> , 96:3584-3589 (1999).
	*C27	Soukup, et al., <i>RNA</i> , 5:1308-1325 (1999).
	*C28	Soukup, et al., <i>Structure</i> , 7(7):783-791 (1999).
	*C29	Soukup, et al., <i>Tren. Biotech.</i> , 17:469-476 (1999).
	*C30	Soukup, et al., in <i>Ribozyme Biochem. Biotech.</i> , Eaton Publishing, Chapter 8, pgs. 149-170, Krupp & Gaur, eds.
	*C31	Soukup, et al., <i>RNA</i> , 7:524-536 (2001).
	*C32	Soukup, et al., <i>J. Mol. Biol.</i> , 298:623-632 (2000).
	*C33	Stetsenko, et al., <i>Nucleosides, Nucleotides & Nucl. Acids</i> , 19(10-12):1751-1764 (2000).
	*C34	Tang, et al., <i>Chem. & Biol.</i> , 4:453-459 (1997).
	*C35	Tang, et al., <i>Nucl. Acids Res.</i> , 26(18):4214-4221 (1998).
	*C36	Tang, et al., <i>RNA</i> , 3:914-925 (1997).
	*C37	Trail, et al., <i>Cancer Immunol. Immunother.</i> , 52(5):328-337 (2003).
✓	*C38	Tung, C.H., <i>Bioconjug. Chem.</i> , 11(5):605-618 (2000).

A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/600,007, filed June 18, 2003, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Tracy Vivlemore/	Date Considered	06/28/2006
-----------------------	-------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Express Mail Label: EV 392124055 US
 Date of Deposit: December 20, 2004


Page 1 of 4
 Attorney Docket No.: 23239-531 CIP

Please type a plus sign (+) in this box



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/826,077
	Filing Date	April 15, 2004
	First Named Inventor	Stanton
	Group Art Unit	1845 / 1635
	Examiner Name	Not Assigned
	Attorney Docket Number	23239-531 CIP

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
TV	A9	4,683,195	07/28/87	Mullis			
	A10	4,870,162	09/26/89	Chari et al.			
	A11	4,935,363	06/19/90	Brown et al.			
	A12	5,070,010	12/03/91	Hsu			
	A13	5,208,020	05/04/93	Chari et al.			
	A14	5,270,163	12/14/93	Gold et al.			
	A15	5,416,064	5/16/95	Chari et al.			
	A16	5,459,015	10/17/95	Janic et al.			
	A17	5,475,092	12/12/95	Chari et al.			
	A18	5,635,615	06/03/97	Allen et al.			
	A19	5,654,151	08/05/97	Allen et al.			
	A20	5,705,337	01/06/98	Gold et al.			
	A21	5,723,323	03/03/98	Kaufmann et al.			
	A22	5,756,291	05/26/98	Griffen et al.			
	A23	5,763,173	06/09/98	Gold et al.			
	A24	5,846,545	12/08/98	Chari et al.			
	A25	6,011,020	01/04/00	Gold et al.			
	A26	6,013,443	01/11/00	Heiliq et al.			
	A27	6,020,130	02/01/00	Gold et al.			
	A28	6,232,071B1	05/15/01	Hicke et al.			
	A29	6,340,701B1	01/22/02	Chari et al.			
	A30	6,372,738B2	04/18/02	Chari et al.			
	A31	6,610,841 B1	08/26/03	Warren et al.			
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
TV	A32	2003/0064931A1	04/03/03	Gallivan, J.			



Express Mail Label: EV 392124055 US
Date of Deposit: December 20, 2004

Page 2 of 4
Attorney Docket No.: 23239-531 CIP

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
TV	B8	UK 2 183 661 A	Ballivet, M. et al.	06/10/87		
	B9	PCT W089/06694	Trustees of the University of Pennsylvania	07/27/89		
	B10	PCT W091/14436	Isis Pharmaceuticals, Inc.	10/03/91		
	B11	PCT W091/19813	The University of Colorado Foundation	12/26/91		
	B12	PCT W092/05285	Fred Hutchinson Cancer Research Center	04/02/92		
	B13	PCT W092/14842	Gilead Sciences, Inc.	09/03/92		
	B14	PCT W092/14843	Gilead Sciences, Inc.	09/03/92		
	B15	PCT W099/30561	Nexstar Pharmaceuticals, Inc.	06/24/99		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
TV	C40	Andrake (1988) Proc. Natl. Acad. Sci. USA 85:7942-46
	C41	Carey et al. (1983) Biochem. 22(11):2601-10
	C42	Charlton, J., et al., Chemistry & Biology, 4:809-816, (Nov. 1997)
	C43	Cload, Sharon, The Aptamer Therapeutics Company, UBS Global Life Sciences Conference, The Plaza Hotel, New York, September 23, 2003.
	C44	Cohen et al. (1969) Proc. Natl. Acad. Sci. USA 63:458-64
	C45	Davis, Jeffrey, et al., Methods in Enzymology, Vol. 267:302-14 (1996)
	C46	Ellington & Szostak (1990) Abstracts of papers presented at the 1990 meeting on RNA Processing, Cold Spring Harbor Laboratory, Cold Springs Harbor, NY, p. 84
	C47	Fitzwater, Tim, et al., A Select Primer, Methods in Enzymology, Vol. 267:275-301 (1996)
	C48	Hicke, Brian, et al., Vol. 106, No. 8, 923-28 (October 2000)
	C49	Joyce (1989) Gene, RNA: Catalysis, Splicing and Evolution, 82:83-87
	C50	Joyce & Inoue (1989) Nucleic Acids Research 17:711-22
	C51	Kacian et al. (1972) Proc. Natl. Acad. Sci. USA 69:3038-42
	C52	Kadonaga et al. (1986) Proc. Natl. Acad. Sci. USA 83:5889-93
	C53	Kinzler & Vogelstein (1989) Nucleic Acids Research 17:3645-53
	C54	Kinzler et al. (1990) Mol. Cell. Biol. 10:634-42
	C55	Knox, S., Et al., Clinical Cancer Research, Vol. 6, 406-414, (Feb. 2000)
	C56	Kramer et al. (1974) J. Mol. Biol. 89:719-36
	C57	Lestienne et al. (1983) Biochimie. 65:49-52



Express Mail Label: EV 392124055 US
Date of Deposit: December 20, 2004

Page 3 of 4
Attorney Docket No.: 23239-531 CIP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
TV	C58	Levisohn & Spiegelman (1968) PNAS USA 60:866-72
	C59	Levisohn & Spiegelman (1969) PNAS USA 63:805-11
	C60	Lin, Y., et al., Proc. Natl Acad. Sci. USA, Vol. 92, 11044-48, (Nov. 1995)
	C61	Liu, C., et al., Proc. Natl., Acad. Sci, USA, Vol. 93, 8618-8623, (August 1996)
	C62	Ma and Ptashne (1987) Cell 51: 113-19
	C63	Maniatis (1982) Molecular Cloning: a Laboratory Manual, Cold Spring Harbor, NY. Page 118
	C64	Maniatis et al. (1987) Science 236: 1237-45
	C65	Miele et al. (1983) J. Mol. Biol. 171:281-95
	C66	Mills et al. (1967) Proc. Natl. Acad. Sci. USA 58:217-20
	C67	Mills et al (1973) Science 180:916-27
	C68	Min et al (1988) Nucleic Acids Res. 16:5075-88
	C69	Muesing et al. (1985) Nature 313:450-58
	C70	Oliphant & Struhl (1987) Methods in Enzymology 155:568-82
	C71	Oliphant & Struhl (1988) Nucleic Acids Research 16:7673-83
	C72	Oliphant et al. (1986) Gene 44:177-83
	C73	Oliphant et al. (1989) Mol. Cell. Biol. 9:2944-49
	C74	Orgel (1979) Proc. R. Soc. Lon. B205:435-42
	C75	Ou et al. (1988) Science 239:295-97
	C76	Robertson & Joyce (1990) Nature 344:467-68
	C77	Romaniuk et al. (1987) Biochem. 26(6):1563-68
	C78	Ross, S., et al., Cancer Research 62, 2456-2553, (May 1, 2002)
	C79	Saffhill et al. (1970) J. Mol. Biol. 51 :531-39
	C80	Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, NY. Section 8.9-10 8.9-8.10
	C81	Singleton et al., Dictionary of Microbiol. & Molec. Biol., Wiley & Sons, New York, NY, 2 nd ed. P. 270
	C82	Smith, Drew, et al., Chemistry & Biology, 2:741-750 (November 1995)
	C83	Szostak, A Structure and Activity of Ribozymes, in Redesigning the Molecules of Life, (SA Benner ed.) Springer-Verlag Berline Heidelberg, pp. 87-113 (1988)
	C84	Thiesen & Bach (1990) Nucleic Acids Research 18:3203-9
	C85	Uhlenbeck et al. (1983) J. Biomolecular Structure and Dynamics 1 :539-52
	C86	Watson et al (1987) Molecular Biology of the Gene. Benjamin/Cummings Publishing Co., Inc. California, pp. 267,295,323,361,394,396,397 and 405

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C87	Wilson, Chuck, Aptamer Therapeutics: Recent Developments, The Hutton, London, February 16, 2004

Examiner Signature	/Tracy Vivlemore/	Date Considered	06/28/2006
-----------------------	-------------------	--------------------	------------

EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

TRA 1989157v1

Express Mail Label: EV 695510657 US
Date of Deposit: March 2, 2006



Page 1 of 1
Attorney Docket No.: 23239-531 CIP

Please type a plus sign (+) in this box




Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number		10/826,077	
				Filing Date		April 15, 2004	
				First Named Inventor		Stanton	
				Group Art Unit		1635	
				Examiner Name		Jon Benjamin Ashen	
				Attorney Docket Number		23239-531 CIP	
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)		Date of Publication	Translation Yes No	
OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
TV	*C88	Bodey et al. <i>Anticancer Res.</i> , 16:661-674 (1996)					
	*C89	Brody et al. <i>Rev. Mol. Biotechnol.</i> , 74:5-13 (2000)					
	*C90	George, D. <i>Sem. Oncol.</i> , 28(5 - Supl. 17):27-33 (2001)					
	*C91	Gilliland et al. <i>Proc. Natl. Acad. Sci. USA</i> , 77(8):4539-4543 (1980)					
	*C92	Jayasema, S. <i>Clin. Chem.</i> , 45(9):1628-1650 (1999)					
	*C93	Lavrovsky et al. <i>Biochem. Mol. Med.</i> , 62:11-22 (1997)					
	*C94	Pastan et al. <i>Science</i> , 254:1173-1177 (1991)					
	*C95	Pietras et al. <i>Cancer Res.</i> , 61(7):2929-2934 (2000)					
	*C96	Pirker, R. <i>J. Cancer Res. Clin. Oncol.</i> , 114(4):385-393 (1988)					
	*C97	Siegall, C. <i>Cancer</i> , 74(3):1006-1012 (1994)					
	*C98	Waldmann, T. <i>Science</i> , 252:1657-1661 (1991)					
	*C99	Supplementary European Search Report for EP 03 76 0481, mailed December 28, 2005.					

* A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/600,007, filed June 18, 2003, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Tracy Vivlemore/	Date Considered	06/28/2006
-----------------------	-------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Express Mail No.: EV 460337459 US
Date of Deposit: April 21, 2006

Page 1 of 1
Attorney Docket No.: 23239-531 CIP

Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number		10/826,077	
				Filing Date		April 15, 2004	
				First Named Inventor		Stanton	
				Group Art Unit		1635	
				Examiner Name		Jon Benjamin Ashen	
				Attorney Docket Number		23239-531 CIP	
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
TV	*A33	6,333,333 B1	12/25/01	Bishop et al.	514	290	
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
TV	*A34	2003/0050331 A1	03/13/03	Ng et al.	514	411	
TV	*A35	2004/0022727 A1	02/05/04	Stanton et al.	424	1.49	
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
TV	*B16	WO	03/106659	ARCHEMIX CORP.	12/24/03		
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
TV	*C100	International Search Report for PCT/US05/12797, mailed February 13, 2006.					

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/600,007, filed June 18, 2003, and relied upon for an earlier filing date under 35 U.S.C. § 120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Tracy Vivlemore/	Date Considered	06/28/2006
-------------------------------	-------------------	----------------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Please type a plus sign (+) in this box



Modified Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/826,077
Filing Date	April 15, 2004
First Named Inventor	Stanton et al.
Group Art Unit	1635
Examiner Name	Ashen, Jon B.
Attorney Docket Number	23239-531 CIP

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
TV	*A36	3,710,795	01/16/73	Higuchi et al.			
	*A37	4,137,230	01/30/79	Hashimoto et al.			
	*A38	4,360,462	11/23/82	Higashide et al.			
	*A39	4,861,587	08/29/89	Kida et al.			
	*A40	4,808,520	02/28/89	Dattagupta et al.			
	*A41	4,959,309	09/25/90	Dattagupta et al.			
	*A42	5,142,047	08/25/92	Summerton et al.			
	*A43	5,262,564	11/16/93	Kun et al.			
	*A44	5,279,833	01/18/94	Rose			
	*A45	5,338,671	08/16/94	Scalice et al.			
	*A46	5,475,096	12/12/95	Gold et al.			
	*A47	5,496,938	03/05/96	Gold et al.			
	*A48	5,503,978	04/12/96	Schneider et al.			
	*A49	5,563,255	10/08/96	Monia et al.			
	*A50	5,567,588	10/22/96	Gold et al.			
	*A51	5,580,737	12/03/96	Polisky et al.			
	*A52	5,614,503	03/25/97	Chaudhary et al.			
	*A53	5,631,237	05/20/97	Dzau et al.			
	*A54	5,631,359	05/20/97	Chowrira et al.			
	*A55	5,637,459	6/10/97	Burke et al.			
	*A56	5,648,214	07/15/97	Nieuwlandt et al.			
	*A57	5,660,985	08/26/97	Pieken et al.			
	*A58	5,668,264	09/16/97	Janjic et al.			
	*A59	5,674,685	10/07/97	Janjic et al.			
	*A60	5,674,980	10/07/97	Frankel et al.			
	*A61	5,700,923	12/23/97	Goodchild et al.			
	*A62	5,707,796	01/13/98	Gold et al.			
	*A63	5,741,679	04/21/98	George et al.			
	*A64	5,789,157	08/04/98	Jensen et al.			
↓	*A65	5,763,177	06/09/98	Gold et al.			
	*A66	5,767,263	6/16/98	Usman et al.			

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
TV	*A67	5,789,157	08/04/98	Jensen et al.			
	*A68	5,804,604	09/08/98	Frankel et al.			
	*A69	5,824,490	10/20/98	Coffey et al.			
	*A70	5,859,228	01/12/99	Janjic et al.			
	*A71	5,998,142	12/07/99	Gold et al.			
	*A72	6,051,698	04/18/00	Janjic et al.			
	*A73	6,063,566	05/16/00	Joyce			
	*A74	6,168,778	01/02/01	Janjic et al.			
	*A75	6,207,816	03/27/01	Gold et al.			
	*A76	6,229,002	05/08/01	Janjic et al.			
	*A77	6,261,774	07/17/01	Pagratitis et al.			
	*A78	6,333,410	12/25/01	Chari et al.			
	*A79	6,949,379	08/22/02	Ramachandra			
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
TV	*A80	US2002/0102694	08/01/02	Breaker et al.			

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
TV	*B17	EP	0 553 838	Kabushiki Kaisha Toshiba	08/04/93	
	*B18	EP	0592035	Scalice et al.	04/13/94	
	*B19	PCT	WO90/10448	Genentech, Inc.	9/20/90	
	*B20	PCT	WO94/08050	Nexagen, Inc.	04/14/94	
	*B21	PCT	WO98/18480	Nexstar Pharmaceuticals, Inc.	05/07/98	
	*B22	PCT	WO02/26867	The Regents of the University of California	04/04/02	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
TV	*C101	Agrawal and Zhang (1997) Ciba Found. Symp 209:60-78
	*C102	Akhtar and Agrawal (1997), Trends Pharmacol. Sci 18(1):12-18
	*C103	Antopolsky, <i>et al.</i> (1999), Bioconjug. Chem. 10(4): 598-606
	*C104	Astriab-Fisher, <i>et al.</i> (2000), Biochem. Pharmacol. 60(1): 83-90
	*C105	Bell, <i>et al.</i> (1999), In Vitro Cell. Dev. Biol. Anim. 35(9): 533-42
	*C106	Bock et al., (1992) Nature 355:564-566
	*C107	Brady <i>et al.</i> (2002) J. Med. Chem., 45:4706-4715
	*C108	Carrasquillo, <i>et al.</i> (2003), Invest. Ophthalmology Vis. Sci. 44(1): 290-9
	*C109	Chen et al. (1994) Biochem. 33:8746-8756
	*C110	Chen, <i>et al.</i> (2003), Proc. Natl. Acad. Sci. U.S.A. 100(16): 9226-31
	*C111	Church et al. (1984) PNAS USA 81:1991-1995
	*C112	Cotten, <i>et al.</i> , (1991) Nucl. Acid Res. 19:2629-2635
	*C113	Crooke (1997), Adv. Pharmacol. 40: 1-49
	*C114	Daniels, <i>et al.</i> (2002), Anal. Biochem. 305(2): 214-26
	*C115	Dehouck et al., (1996) Biology and Physiology of the Blood Brain Barrier, Couraud and Scherman eds., Chapter 23, pp. 143-146
	*C116	de Smidt, <i>et al.</i> (1991), Nucleic Acids Res. 19(17): 4695-4700
	*C117	Eggen and Georg, (2002) Medicinal Research Reviews, 22(2):85-101
	*C118	Fedor and Uhlenbeck, (1990) Proc. Natl. Acad. Sci. USA 87: 1668-1672
	*C119	Froehler <i>et al.</i> , (1986) Nucl. Acid Res. 14:5399-5467
	*C120	Froehler <i>et al.</i> , (1986) Tet. Lett. 27:5575-5578
	*C121	Gath et al., (1996) Biology and Physiology of the Blood Brain Barrier, Couraud and Scherman eds., Chapter 25, pp. 153-158
	*C122	Green, <i>et al.</i> (1995), Chem. Biol. 2: 683-95
	*C123	Greenwald, <i>et al.</i> , (1995) J. Org. Chem., 60:331-336
	*C124	Griffin, <i>et al.</i> (1993), Gene 137(1): 25-31
	*C125	Grindel, <i>et al.</i> (1998), Antisense Nucleic Acid Drug Dev. 8(1): 43-52
	*C126	Hamann <i>et al.</i> (2002) Bioconjugate Chem., 13: 47-58
	*C127	Hampel and Tritz, (1989) Biochemistry 28: 4929-4933
	*C128	Harris <i>et al.</i> , (2003) Nature 2: 214-221

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
TV	*C129	Haseloff and Gerlach, (1988) Nature 334: 585-591
	*C130	Hirose <i>et al.</i> , (1978) Tet. Lett., 28:2449-2452
	*C131	Hobbs, <i>et al.</i> , (1973) Biochemistry 12:5138-5145
	*C132	Jablonski <i>et al.</i> , (1986) Nuc Acids Res. 14(15):6115-6128
	*C133	Jashcke <i>et al.</i> , (1994) Nuc. Acids Res. 22:4810-4817
	*C134	Jellinek, <i>et al.</i> (1995) Biochemistry 34(36): 11363-11372
	*C135	Jenison, <i>et al.</i> (1998), Antisense Nucleic Acid Drug Dev. 8(4): 265-79
	*C136	Kellogg <i>et al.</i> , (1994) BioTechniques 16:1134-1137
	*C137	Khali, <i>et al.</i> (2003), J. Virol. 77(23): 12692-8
	*C138	Koizumi <i>et al.</i> , FEBS Lett. 239: 285-288 (1988)
	*C139	Kraus, <i>et al.</i> , (1998) Journal of Immunology 160:5209-5212
	*C140	Lebedeva, <i>et al.</i> (2000), Eur. J. Pharm. Biopharm. 50(1): 101-119
	*C141	Lewis, <i>et al.</i> , (2002) Bioconjugate Chemistry 13(6):1176-1180
	*C142	Lin, <i>et al.</i> , (1994) Nucl. Acids Res. 22:5229-5234
	*C143	Manoharan (2002), Antisense Nucleic Acid Drug Dev. 12(2): 103-128
	*C144	Monteith and Levin (1999), Toxicol. Pathol. 27(1): 8-13
	*C145	Padilla <i>et al.</i> , (2002) Nucleic Acids Research, 30(24):e138, pp. 1-4
	*C146	Pagratias, <i>et al.</i> , (1997) Nat. Biotechnol 15:68-73
	*C147	Peng, <i>et al.</i> (2001) Antisense Nucleic Acid Drug Dev. 11(1): 15-27
	*C148	Pieken, <i>et al.</i> , (1991) Science 253:314-317
	*C149	Pietersz, <i>et al.</i> (2001) Vaccine 19: 1397-1405
	*C150	Reyderman and Stavchansky (1998) Pharmaceutical Research 15(6): 904-910
	*C151	Richardson, <i>et al.</i> (2000), Biochem. Pharmacol. 59(9): 1045-1052
	*C152	Richardson, <i>et al.</i> (2002), Chem. Res. Toxicol. 15(7): 922-926
	*C153	Rothbard, <i>et al.</i> (2000), Nat. Med. 6(11): 1253-1257
	*C154	Rothbard, J <i>et al.</i> (2002), J. Med. Chem. 45(17): 3612-3618
	*C155	Ruckman, <i>et al.</i> (1998), J. Biol. Chem. 273(32): 20556-20567
	*C156	Smith and Steitz (1997), Cell 89(5): 669-672
	*C157	Smith <i>et al.</i> (1985) Nuc Acids Res. 13(7):2399-2412
	*C158	Sood <i>et al.</i> , (1977) Nucl. Acid Res. 4:2757-2765
	*C159	Sproat, <i>et al.</i> , Nucl. Acid Res. 19:733-738 (1991)
	*C160	Srinivasan and Iversen (1995), J. Clin. Lab. Anal. 9(2): 129-137
	*C161	Tavitian, <i>et al.</i> (1998), Nat. Med. 4(4): 467-471
	*C162	Tanchou <i>et al.</i> (1994) Aids Research and Human Retroviruses 10:983-993
	*C163	Tucker <i>et al.</i> , (1999), J. Chromatography B. 732: 203-212
	*C164	Tuerk <i>et al.</i> , (1992) Proc. Natl. Acad. Sciences 89(15):6988-6992
	*C165	Uhlenbeck, (1987) Nature 328: 596-600
	*C166	Uhlmann, <i>et al.</i> (2000), Methods Enzymol. 313: 268-284
	*C167	Usman <i>et al.</i> (2000) Clin. Invest. 106:1197-1202

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
TV	*C168	Vaish, <i>et al.</i> (2003), Biochemistry 42(29): 8842-8851
	*C169	Vives, <i>et al.</i> (1997), J. Biol. Chem. 272(25): 16010-16017
	*C170	Watson, <i>et al.</i> (2000), Antisense Nucleic Acid Drug Dev. 10(2): 63-75
	*C171	Wlotzka, <i>et al.</i> (2002), Proc. Natl. Acad. Sci. U.S.A. 99(13): 8898-8902
	*C172	Zubin, <i>et al.</i> (1999), FEBS Lett. 456(1): 59-62

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/600,007, filed June 18, 2003, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Tracy Vivlemore/	Date Considered	06/28/2006
-----------------------	-------------------	--------------------	------------

EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.